Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus of diverse genetic types

Background: Ceftobiprole was approved by the United States (US) Food and Drug Administration (FDA) in 2024 and by the European Medicines Agency in 2013 for the treatment of pneumonia, bacterial skin and skin structure infections, and Staphylococcus aureus bloodstream infections. Numerous methicillin...

Full description

Bibliographic Details

Published in:	Journal of Global Antimicrobial Resistance
Main Authors:	Marisa L. Winkler, John H. Kimbrough, Helio S. Sader, Mariana Castanheira, Rodrigo E. Mendes
Format:	Article
Language:	English
Published:	Elsevier 2025-09-01
Subjects:	MRSA Ceftobiprole Clonal complex Novel agents Surveillance
Online Access:	http://www.sciencedirect.com/science/article/pii/S2213716525001754